Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Change in Account Payables (2016 - 2017)

Eledon Pharmaceuticals filings provide 5 years of Change in Account Payables readings, the most recent being -$154000.0 for Q1 2017.

  • On a quarterly basis, Change in Account Payables fell 122.71% to -$154000.0 in Q1 2017 year-over-year; TTM through Mar 2017 was -$1.6 million, a 4.01% decrease, with the full-year FY2016 number at -$778000.0, down 275.62% from a year prior.
  • Change in Account Payables hit -$154000.0 in Q1 2017 for Eledon Pharmaceuticals, up from -$456000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.7 million in Q1 2015 to a low of -$1.8 million in Q2 2015.
  • Median Change in Account Payables over the past 5 years was -$222500.0 (2014), compared with a mean of -$46785.7.
  • Biggest five-year swings in Change in Account Payables: surged 234.46% in 2015 and later crashed 5233.33% in 2016.
  • Eledon Pharmaceuticals' Change in Account Payables stood at -$926000.0 in 2013, then fell by 21.38% to -$1.1 million in 2014, then surged by 60.5% to -$444000.0 in 2015, then fell by 2.7% to -$456000.0 in 2016, then surged by 66.23% to -$154000.0 in 2017.
  • The last three reported values for Change in Account Payables were -$154000.0 (Q1 2017), -$456000.0 (Q4 2016), and -$960000.0 (Q3 2016) per Business Quant data.